Clinical trials: Moderate Dementia
Alzheimer's Disease
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored.
- Trial name
- NCT02754830
- Testing
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
This is a 96-week extension study of open-label simufilam 100 mg b.i.d. for mild-to-moderate Alzheimer's disease subjects who completed the Phase 2 study, PTI-125-04. The study will evaluate safety and long-term treatment.
- Trial name
- NCT05352763
- Testing
- simufilam
- Where
- 11 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer Disease, Dementia, Alzheimer Type
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
This is a Phase 2 study to evaluate safety and efficacy in participants with Mild Cognitive Impairment due to Alzheimer's Disease/Prodromal Alzheimer's Disease (referred to as MCI/Prodromal) and mild to moderate dementia due to…
- Trial name
- NCT02322021
- Testing
- E2609
- Where
- 21 sites in United States
- Volunteers
- 70 people
- Sponsor
- Eisai Inc.
Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems
This is an open-label study to investigate the effects of the rivastigmine patch on attention and behavior in Parkinson's disease when associated with memory and/or thinking problems.
- Trial name
- NCT00988117
- Testing
- Rivastigmine Patch 9.5 cm2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Alzheimer Disease, Dementia
Faith-Based Toolbox for African Americans With Dementia
The purpose of this study is to create and test faith-based activities that might be useful for African American adults with moderate and severe dementia and their caregivers.
- Trial name
- NCT04325204
- Testing
- Faith-based Home Activity Toolbox (Faith-HAT)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Emory University
Mild Cognitive Impairment, Mild Dementia
A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD
A study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older with mild cognitive impairment and mild-to-moderate to Alzheimer's disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Alzheimer Disease
- Trial name
- NCT05004688
- Testing
- Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Steven E Arnold, MD
Alzheimer Disease
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks.
- Trial name
- RETHINK-ALZ (NCT04994483)
- Testing
- Simufilam
- Where
- 88 sites in United States, Australia and 1 more
- Volunteers
- 804 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer Disease
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are…
- Trial name
- NCT00912288
- Testing
- Dimebon 20 mg po TID
- Where
- 47 sites in United States, Canada and 6 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
Dementia With Lewy Bodies
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.
- Trial name
- COG1201 (NCT05225415)
- Testing
- CT1812
- Where
- 34 sites in United States
- Volunteers
- 130 people
- Sponsor
- Cognition Therapeutics
Dementia, Alzheimer's Disease
Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia
The purpose of this study is to examine the effects of supplementing Magnesium L-Threonate in people with mild to moderate dementia.
- Trial name
- NCT02210286
- Testing
- Magtein
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University